Who is sponsoring NCT02394704?

NCT02394704 is sponsored by University of Pittsburgh.

What drugs are being tested in NCT02394704?

Interventions in NCT02394704: Sensory attention training.

What condition does NCT02394704 study?

NCT02394704 studies Intrusive Negative Thinking.

Is NCT02394704 still recruiting?

NCT02394704 is currently completed. Last updated 7 December 2021.

Last reviewed 2021-12-07 · How we verify

NCT02394704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intervention for Intrusive Negative Thinking

Completed NA Last updated 7 December 2021

What this trial tests

NA trial testing Sensory attention training in Intrusive Negative Thinking in 194 participants. Completed in 17 August 2021.

Timeline

1 November 2015

Primary endpoint
9 June 2021

17 August 2021

Quick facts

Lead sponsor	University of Pittsburgh
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	194
Start date	1 November 2015
Primary completion	9 June 2021
Estimated completion	17 August 2021
Sites	1 location across United States

Drugs / interventions tested

Sensory attention training

Conditions studied

Intrusive Negative Thinking — all drugs for Intrusive Negative Thinking →

Sponsor

University of Pittsburgh

Who can join

Adults 18 to 65, any sex, with Intrusive Negative Thinking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intrusive negative thinking styles such as rumination are typical of many psychiatric disorders, are difficult to treat, and predict poor treatment outcome. The investigators propose to evaluate a new intervention for negative thinking that capitalizes and builds on the preserved ability to attend to physical sensation. The investigators will examine changes in physiological mechanisms and symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Pittsburgh trials

Trials by the same sponsor.

NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02394704 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 7 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02394704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing